 | • レポートコード：QYR2104Z5967 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥565,500 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥848,250 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,131,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、フォンウィルブランド病（VWD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・フォンウィルブランド病（VWD）治療薬の市場動向 ・企業の競争状況、市場シェア ・フォンウィルブランド病（VWD）治療薬の種類別市場規模（デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他） ・フォンウィルブランド病（VWD）治療薬の用途別市場規模（病院薬局、小売薬局、オンライン薬局） ・フォンウィルブランド病（VWD）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・フォンウィルブランド病（VWD）治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・フォンウィルブランド病（VWD）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・フォンウィルブランド病（VWD）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・フォンウィルブランド病（VWD）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Apollo Therapeutics、Apotex、Bayer、Bio Products Laboratory、CSL、Ferring Pharmaceuticals、Glenmark Pharmaceuticals、Grifols、Octapharma、Takeda） ・結論 |
Von Willebrand Disease is an inherited bleeding disorder that is caused by deficiency or dysfunction of Von Willebrand Factor (VWF). VWF is a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury. This protein also binds to clotting factor VIII (FVIII) in the circulation and stabilizes it.
Symptoms of Von Willebrand Disease include prolonged bleeding from skin lacerations, bleeding from nose and gums, and menorrhagia.
Different types of therapeutics have been utilized in the treatment of von Willebrand Disease, including desmopressin, clot-stabilizing medications, replacement therapies, contraceptives, and others. Desmopressin is extensively used in the treatment of von Willebrand disease.
Market Analysis and Insights: Global Von Willebrand Disease (VWD) Therapeutics Market
The global Von Willebrand Disease (VWD) Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Von Willebrand Disease (VWD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Von Willebrand Disease (VWD) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Von Willebrand Disease (VWD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Von Willebrand Disease (VWD) Therapeutics market.
Global Von Willebrand Disease (VWD) Therapeutics Scope and Market Size
Von Willebrand Disease (VWD) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Von Willebrand Disease (VWD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Desmopressin
Clot-Stabilizing Medication
Fibrinolytic Inhibitors
Replacement Therapy
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Apollo Therapeutics
Apotex
Bayer
Bio Products Laboratory
CSL
Ferring Pharmaceuticals
Glenmark Pharmaceuticals
Grifols
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Von Willebrand Disease (VWD) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Desmopressin
1.2.3 Clot-Stabilizing Medication
1.2.4 Fibrinolytic Inhibitors
1.2.5 Replacement Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Von Willebrand Disease (VWD) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Von Willebrand Disease (VWD) Therapeutics Market Perspective (2016-2027)
2.2 Von Willebrand Disease (VWD) Therapeutics Growth Trends by Regions
2.2.1 Von Willebrand Disease (VWD) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Von Willebrand Disease (VWD) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Von Willebrand Disease (VWD) Therapeutics Industry Dynamic
2.3.1 Von Willebrand Disease (VWD) Therapeutics Market Trends
2.3.2 Von Willebrand Disease (VWD) Therapeutics Market Drivers
2.3.3 Von Willebrand Disease (VWD) Therapeutics Market Challenges
2.3.4 Von Willebrand Disease (VWD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Von Willebrand Disease (VWD) Therapeutics Players by Revenue
3.1.1 Global Top Von Willebrand Disease (VWD) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Von Willebrand Disease (VWD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Von Willebrand Disease (VWD) Therapeutics Revenue
3.4 Global Von Willebrand Disease (VWD) Therapeutics Market Concentration Ratio
3.4.1 Global Von Willebrand Disease (VWD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Von Willebrand Disease (VWD) Therapeutics Revenue in 2020
3.5 Von Willebrand Disease (VWD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Von Willebrand Disease (VWD) Therapeutics Product Solution and Service
3.7 Date of Enter into Von Willebrand Disease (VWD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Von Willebrand Disease (VWD) Therapeutics Breakdown Data by Type
4.1 Global Von Willebrand Disease (VWD) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Type (2022-2027)
5 Von Willebrand Disease (VWD) Therapeutics Breakdown Data by Application
5.1 Global Von Willebrand Disease (VWD) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Von Willebrand Disease (VWD) Therapeutics Market Size (2016-2027)
6.2 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type
6.2.1 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2027)
6.3 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Application
6.3.1 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2027)
6.4 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Country
6.4.1 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Von Willebrand Disease (VWD) Therapeutics Market Size (2016-2027)
7.2 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type
7.2.1 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Application
7.3.1 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Country
7.4.1 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size (2016-2027)
9.2 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type
9.2.1 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Application
9.3.1 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Country
9.4.1 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Apollo Therapeutics
11.1.1 Apollo Therapeutics Company Details
11.1.2 Apollo Therapeutics Business Overview
11.1.3 Apollo Therapeutics Von Willebrand Disease (VWD) Therapeutics Introduction
11.1.4 Apollo Therapeutics Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.1.5 Apollo Therapeutics Recent Development
11.2 Apotex
11.2.1 Apotex Company Details
11.2.2 Apotex Business Overview
11.2.3 Apotex Von Willebrand Disease (VWD) Therapeutics Introduction
11.2.4 Apotex Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.2.5 Apotex Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Von Willebrand Disease (VWD) Therapeutics Introduction
11.3.4 Bayer Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.3.5 Bayer Recent Development
11.4 Bio Products Laboratory
11.4.1 Bio Products Laboratory Company Details
11.4.2 Bio Products Laboratory Business Overview
11.4.3 Bio Products Laboratory Von Willebrand Disease (VWD) Therapeutics Introduction
11.4.4 Bio Products Laboratory Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.4.5 Bio Products Laboratory Recent Development
11.5 CSL
11.5.1 CSL Company Details
11.5.2 CSL Business Overview
11.5.3 CSL Von Willebrand Disease (VWD) Therapeutics Introduction
11.5.4 CSL Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.5.5 CSL Recent Development
11.6 Ferring Pharmaceuticals
11.6.1 Ferring Pharmaceuticals Company Details
11.6.2 Ferring Pharmaceuticals Business Overview
11.6.3 Ferring Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Introduction
11.6.4 Ferring Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.6.5 Ferring Pharmaceuticals Recent Development
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Details
11.7.2 Glenmark Pharmaceuticals Business Overview
11.7.3 Glenmark Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Introduction
11.7.4 Glenmark Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.7.5 Glenmark Pharmaceuticals Recent Development
11.8 Grifols
11.8.1 Grifols Company Details
11.8.2 Grifols Business Overview
11.8.3 Grifols Von Willebrand Disease (VWD) Therapeutics Introduction
11.8.4 Grifols Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.8.5 Grifols Recent Development
11.9 Octapharma
11.9.1 Octapharma Company Details
11.9.2 Octapharma Business Overview
11.9.3 Octapharma Von Willebrand Disease (VWD) Therapeutics Introduction
11.9.4 Octapharma Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.9.5 Octapharma Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Von Willebrand Disease (VWD) Therapeutics Introduction
11.10.4 Takeda Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
11.10.5 Takeda Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Von Willebrand Disease (VWD) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Desmopressin
Table 3. Key Players of Clot-Stabilizing Medication
Table 4. Key Players of Fibrinolytic Inhibitors
Table 5. Key Players of Replacement Therapy
Table 6. Key Players of Others
Table 7. Global Von Willebrand Disease (VWD) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Von Willebrand Disease (VWD) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Von Willebrand Disease (VWD) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Regions (2022-2027)
Table 13. Von Willebrand Disease (VWD) Therapeutics Market Trends
Table 14. Von Willebrand Disease (VWD) Therapeutics Market Drivers
Table 15. Von Willebrand Disease (VWD) Therapeutics Market Challenges
Table 16. Von Willebrand Disease (VWD) Therapeutics Market Restraints
Table 17. Global Von Willebrand Disease (VWD) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Von Willebrand Disease (VWD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Von Willebrand Disease (VWD) Therapeutics as of 2020)
Table 20. Ranking of Global Top Von Willebrand Disease (VWD) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Von Willebrand Disease (VWD) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Von Willebrand Disease (VWD) Therapeutics Product Solution and Service
Table 24. Date of Enter into Von Willebrand Disease (VWD) Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Von Willebrand Disease (VWD) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Von Willebrand Disease (VWD) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Apollo Therapeutics Company Details
Table 65. Apollo Therapeutics Business Overview
Table 66. Apollo Therapeutics Von Willebrand Disease (VWD) Therapeutics Product
Table 67. Apollo Therapeutics Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 68. Apollo Therapeutics Recent Development
Table 69. Apotex Company Details
Table 70. Apotex Business Overview
Table 71. Apotex Von Willebrand Disease (VWD) Therapeutics Product
Table 72. Apotex Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 73. Apotex Recent Development
Table 74. Bayer Company Details
Table 75. Bayer Business Overview
Table 76. Bayer Von Willebrand Disease (VWD) Therapeutics Product
Table 77. Bayer Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Bayer Recent Development
Table 79. Bio Products Laboratory Company Details
Table 80. Bio Products Laboratory Business Overview
Table 81. Bio Products Laboratory Von Willebrand Disease (VWD) Therapeutics Product
Table 82. Bio Products Laboratory Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Bio Products Laboratory Recent Development
Table 84. CSL Company Details
Table 85. CSL Business Overview
Table 86. CSL Von Willebrand Disease (VWD) Therapeutics Product
Table 87. CSL Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 88. CSL Recent Development
Table 89. Ferring Pharmaceuticals Company Details
Table 90. Ferring Pharmaceuticals Business Overview
Table 91. Ferring Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Product
Table 92. Ferring Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 93. Ferring Pharmaceuticals Recent Development
Table 94. Glenmark Pharmaceuticals Company Details
Table 95. Glenmark Pharmaceuticals Business Overview
Table 96. Glenmark Pharmaceuticals Von Willebrand Disease (VWD) Therapeutics Product
Table 97. Glenmark Pharmaceuticals Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 98. Glenmark Pharmaceuticals Recent Development
Table 99. Grifols Company Details
Table 100. Grifols Business Overview
Table 101. Grifols Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 102. Grifols Recent Development
Table 103. Octapharma Company Details
Table 104. Octapharma Business Overview
Table 105. Octapharma Von Willebrand Disease (VWD) Therapeutics Product
Table 106. Octapharma Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 107. Octapharma Recent Development
Table 108. Takeda Company Details
Table 109. Takeda Business Overview
Table 110. Takeda Von Willebrand Disease (VWD) Therapeutics Product
Table 111. Takeda Revenue in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021) & (US$ Million)
Table 112. Takeda Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Desmopressin Features
Figure 3. Clot-Stabilizing Medication Features
Figure 4. Fibrinolytic Inhibitors Features
Figure 5. Replacement Therapy Features
Figure 6. Others Features
Figure 7. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Von Willebrand Disease (VWD) Therapeutics Report Years Considered
Figure 12. Global Von Willebrand Disease (VWD) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Von Willebrand Disease (VWD) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 15. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Regions (2022-2027)
Figure 16. Global Von Willebrand Disease (VWD) Therapeutics Market Share by Players in 2020
Figure 17. Global Top Von Willebrand Disease (VWD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Von Willebrand Disease (VWD) Therapeutics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Von Willebrand Disease (VWD) Therapeutics Revenue in 2020
Figure 19. Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 20. Global Von Willebrand Disease (VWD) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 21. North America Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2016-2027)
Figure 23. North America Von Willebrand Disease (VWD) Therapeutics Market Share by Application (2016-2027)
Figure 24. North America Von Willebrand Disease (VWD) Therapeutics Market Share by Country (2016-2027)
Figure 25. United States Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2016-2027)
Figure 29. Europe Von Willebrand Disease (VWD) Therapeutics Market Share by Application (2016-2027)
Figure 30. Europe Von Willebrand Disease (VWD) Therapeutics Market Share by Country (2016-2027)
Figure 31. Germany Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Von Willebrand Disease (VWD) Therapeutics Market Share by Region (2016-2027)
Figure 41. China Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2016-2027)
Figure 49. Latin America Von Willebrand Disease (VWD) Therapeutics Market Share by Application (2016-2027)
Figure 50. Latin America Von Willebrand Disease (VWD) Therapeutics Market Share by Country (2016-2027)
Figure 51. Mexico Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Von Willebrand Disease (VWD) Therapeutics Market Share by Country (2016-2027)
Figure 57. Turkey Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Von Willebrand Disease (VWD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Apollo Therapeutics Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 61. Apotex Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 62. Bayer Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 63. Bio Products Laboratory Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 64. CSL Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 65. Ferring Pharmaceuticals Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 66. Glenmark Pharmaceuticals Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 67. Grifols Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 68. Octapharma Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 69. Takeda Revenue Growth Rate in Von Willebrand Disease (VWD) Therapeutics Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
世界のフォンウィルブランド病治療市場 2021：企業別、地域別、種類・用途別 The Von Willebrand Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…- 世界の口内乾燥症（口渇症）治療薬市場規模・現状・予測（2021年-2027年） Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack …
- 世界のクッシング病治療市場規模・現状・予測（2021年-2027年） Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal wit…
- 世界の抗血友病因子（AHF）・フォンウィルブランド因子（VWF）複合体市場規模・現状・予測（2021年-2027年） Antihemophilic and von Willebrand factor complex is a combination medicine used to treat or prevent bleeding episodes in people with von Willebrand disease. Antihemophilic and von Willebrand factor complex is also used to treat or prevent bleeding episodes in people with hemophilia A. Market Analysi…
- 世界の希少内分泌疾患治療市場規模・現状・予測（2021年-2027年） The endocrine system is a chemical messenger system consisting of hormones, the group of glands of an organism that carry those hormones directly into the circulatory system to be carried towards distant target organs and the feedback loops of homeostasis that the hormones drive. The rare endocrine …